1,728 件 ・ 関連度順
概要と使いどころ
Prisma Postgres setup and operations guidance across Console, create-db CLI, Management API, and Management API SDK. Use when creating Prisma Postgres databases, working in Prisma Console, provisioning with create-db/create-pg/create-postgres, or integrating programmatic provisioning with service tokens or OAuth.
日本語の概要は準備中です。原文の説明を表示しています。
Comprehensive guidance for implementing asynchronous Python applications using asyncio, concurrent programming patterns, and async/await for building high-performance, non-blocking systems.
日本語の概要は準備中です。原文の説明を表示しています。
Expert guidance for building modern Android UIs with Jetpack Compose, covering state management, navigation, performance, and Material Design 3.
日本語の概要は準備中です。原文の説明を表示しています。
You are an accessibility expert specializing in WCAG compliance, inclusive design, and assistive technology compatibility. Conduct audits, identify barriers, and provide remediation guidance.
日本語の概要は準備中です。原文の説明を表示しています。
Prepares statistical reports for clinical trials following CONSORT 2025, SPIRIT 2025, ICH E9(R1) estimands, and FDA 2023 covariate adjustment guidance. Covers Table 1 generation, analysis populations (ITT/FAS/PP/Safety), the 5 ICH E9(R1) intercurrent-event strategies, MMRM under MAR (mmrm), reference-based MI (rbmi J2R/CR/CIR), Permutt tipping-point sensitivity, and Rubin's-rules vs frequentist variance debate. Use when preparing regulatory submissions, defining estimands, or implementing missing-data sensitivity analyses.
日本語の概要は準備中です。原文の説明を表示しています。
Queries PharmGKB / CPIC / DPWG for drug-gene interactions; calls CYP2D6/CYP2C9/CYP2C19/DPYD/TPMT/NUDT15/UGT1A1/SLCO1B1 star alleles and phenotype with PharmCAT, Cyrius (CYP2D6 structural variants), Aldy, Stargazer; applies Caudle 2020 activity-score translation. Use when implementing pharmacogenomic-guided prescribing, applying CPIC vs DPWG guidance, screening HLA risk alleles for ICI / antiepileptics / abacavir, or interpreting compound TPMT+NUDT15 thiopurine risk.
日本語の概要は準備中です。原文の説明を表示しています。
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
日本語の概要は準備中です。原文の説明を表示しています。
Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.
日本語の概要は準備中です。原文の説明を表示しています。
Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.
日本語の概要は準備中です。原文の説明を表示しています。
Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.
日本語の概要は準備中です。原文の説明を表示しています。
Analyzes CUT&RUN (Skene Henikoff 2017) and CUT&Tag (Kaya-Okur 2019) chromatin profiling data. Handles SEACR vs MACS2 peak calling (with the btaf375 2025 benchmark guidance), pA-MNase vs pA-Tn5 vs pAG-Tn5 chimera differences, E. coli spike-in carryover normalization, IgG-only control logic (no input), characteristic fragment-size signatures (25-75 bp for CUT&Tag), and lower depth requirements (5M reads typical vs 25M for ChIP). Use when calling peaks from CUT&RUN/CUT&Tag, scaling by E. coli spike-in carryover, choosing SEACR norm mode, or comparing CUT&RUN/Tag results to traditional ChIP.
日本語の概要は準備中です。原文の説明を表示しています。
Trim multiple sequence alignments using ClipKIT, trimAl, BMGE, Divvier, or HMMcleaner with mode selection guidance per downstream goal. Use when removing unreliable columns or contaminating residues before phylogenetic inference, HMM building, or selection analysis.
日本語の概要は準備中です。原文の説明を表示しています。
Add MAUI DevFlow to a .NET MAUI project with agent package references, MauiProgram.cs registration, Blazor WebView support, GTK variants, Central Package Management guidance, and verification commands. USE FOR: first-time DevFlow setup, reviewing what files to edit, choosing DevFlow packages, or continuing after `maui devflow init` installs skills. DO NOT USE FOR: troubleshooting an already-integrated app that cannot connect, iterative app debugging, UI inspection, or generic MAUI build failures (use maui-devflow-debug). INVOKES: maui devflow CLI and dotnet CLI.
日本語の概要は準備中です。原文の説明を表示しています。
Use this skill when the user asks how to build, measure, or improve safety culture in a motor carrier — leading vs lagging safety indicators, blame-free reporting, near-miss programs, safety committee structure, monthly safety meetings, ATA Safety Management Program guidance, and how to evaluate cultural maturity. Reference ATA SMP + DOT safety culture research.
日本語の概要は準備中です。原文の説明を表示しています。
Use this skill when a driver wants to use a CMV for personal travel after duty hours. Covers what qualifies as legitimate personal conveyance vs. work-related driving, FMCSA guidance on lodging/meals/home travel, and documentation requirements.
日本語の概要は準備中です。原文の説明を表示しています。
Use this skill to evaluate whether credit reports are appropriate for driver applicant screening. Covers EEOC guidance, FCRA, and common carrier policies.
日本語の概要は準備中です。原文の説明を表示しています。
Use this skill when the user asks about FMCSA's Crash Preventability Determination Program (CPDP) — how to dispute that a crash was non-preventable, eligible crash types, evidence requirements, how preventability findings affect SMS scoring + safety ratings, the difference between "preventability" and "fault," and the National Crash Preventability Program. Cite FMCSA CPDP guidance.
日本語の概要は準備中です。原文の説明を表示しています。
Generate competitive SEO content briefs with per-section word counts, competitor scoring, keyword density guidance, and page-type templates. Supports both new page briefs and improve-existing-page briefs. Use when user says "content brief", "write a brief", "content outline", "blog brief", "service page brief", "brief for", "writing brief", "content plan", or "outline for".
日本語の概要は準備中です。原文の説明を表示しています。
Perform language and framework specific security best-practice reviews and suggest improvements. Use when the user explicitly requests security best practices guidance, a security review/report, or secure-by-default coding help. Trigger only for supported languages (python, javascript/typescript, go), and not for general debugging or non-security tasks.
日本語の概要は準備中です。原文の説明を表示しています。
Build voice AI agents with LiveKit Cloud and the Agents SDK. Use when the user asks to "build a voice agent", "create a LiveKit agent", "add voice AI", "implement handoffs", "structure agent workflows", or is working with LiveKit Agents SDK. Provides opinionated guidance for the recommended path: LiveKit Cloud + LiveKit Inference. REQUIRES writing tests for all implementations.
日本語の概要は準備中です。原文の説明を表示しています。
Guide for when to use and when not to use return validators in Convex functions. Use this skill whenever the user is writing Convex queries, mutations, or actions and needs guidance on return value validation. Also trigger when the user asks about Convex type safety, runtime validation, AI-generated Convex code, Convex AI rules, Convex security best practices, or when they're debugging return type issues in Convex functions. Trigger this skill when users mention "validators", "returns", "return type", or "exact types" in the context of Convex development. Also trigger when writing or reviewing Convex AI rules or prompts that instruct LLMs how to write Convex code.
日本語の概要は準備中です。原文の説明を表示しています。
Combine React's official "You Might Not Need an Effect" guidance with this project's stricter no direct useEffect stance. Use when writing, reviewing, or refactoring React components that might reach for useEffect, derived state, event relays, reset logic, subscriptions, or client fetching.
日本語の概要は準備中です。原文の説明を表示しています。
Comprehensive toolkit for writing high-quality computer science research papers (conference, journal, thesis). Provides narrative construction guidance, sentence-level clarity principles (Gopen & Swan), academic phrasebank, CS-specific conventions, and section-by-section quality checklists. Use when assisting with academic paper writing, revision, or structure planning across all stages from drafting to submission.
日本語の概要は準備中です。原文の説明を表示しています。